Meet our Team
Our leadership team has the clinical expertise and commercial acumen to identify, innovate, and commercialize a diversified portfolio of high-margin products in attractive markets with experience in direct-to-consumer (DTC), physician, and professional market development to drive adoption of our medical technologies toward standard of care.
LISHAN AKLOG, MD
Chief Executive Officer
Lishan Aklog, M.D. has served as Lucid’s Chairman and Chief Executive Officer since its IPO in October 2021 and previously served as its Executive Chairman since its inception in 2018. Dr. Aklog also co-founded and has served as Chairman and Chief Executive Officer of Lucid’s parent company, PAVmed Inc (Nasdaq: PAVM) since its inception in 2014, and as Executive Chairman of PAVmed’s other major subsidiary, digital health company Veris Health Inc., since its inception.
Chief Financial Officer
Dennis M. McGrath has served as the Company’s Executive Vice President and Chief Financial Officer since March 2017.
Previously, from 2000 to 2017 Mr. McGrath served in several senior level positions of PhotoMedex, Inc. (Nasdaq: PHMD), a global manufacturer and distributor of medical device equipment and services, including from 2011 to 2017 as director, President, and Chief Financial Officer.
SHAUN ONEIL, MBA
President & Chief Operating Officer
Shaun M. O’Neil has served as the Company's President & Chief Operating Officer since November of 2023. Previously, O’Neil served as the Company’s Chief Commercial Officer.
O'Neil leads strategic initiatives at Lucid Diagnostics including the design and launch of commercial operations, sales and marketing strategy, market access, as well and the management of Lucid's CLIA-certified laboratory, Lucid Dx Labs.
Stan Lapidus is the Vice Chairman and lead independent director of Lucid Diagnostics. Mr. Lapidus is an inventor and entrepreneur who currently serves on a number of healthcare and medical technology boards.
He’s been founding CEO of three medical diagnostics companies. Two of them have been among the most successful diagnostics startups of all time:
Cytyc Corp., which he founded in 1987, revolutionized early detection of cervical cancer through its development of the modern Pap test—the ThinPrep. The two ThinPrep prototypes are at the Smithsonian’s American Museum of National History.
EXACT Sciences, which he founded in 1995, pioneered non-invasive early detection of colorectal cancer through its Cologuard test. Since its introduction, Cologuard has become the fastest-growing test in the history of the diagnostics industry.
SUMAN VERMA, MD PhD
Chief Scientific Officer
Dr. Suman Verma is Senior Vice President & Chief Scientific Officer of Lucid Diagnostics and oversees research, development, and analytic validation work on the EsoGuard Esophageal DNA Test at Lucid’s CLIA-certified, CAP-accredited laboratory in Lake Forest, CA.
Dr. Verma has more than a decade of experience in the development and implementation of molecular diagnostic assays using the full spectrum of cutting edge molecular biologic techniques and technologies.
DEEPIKA LAKHANI, PhD
Chief Regulatory & Quality Officer
Deepika Lakhani is Senior Vice President and Chief Regulatory & Quality Officer of Lucid Diagnostics.
She is an internationally recognized regulatory professional, with over fifteen years of experience, and has received many awards for excellence and leadership. She spent over a decade at the Food and Drug Administration (FDA), including at both the Center for Drugs Evaluation and Research at the FDA and Center for Devices and Radiological Health, where she reviewed, led cross-disciplinary teams, and contributed to policies impacting drugs, biologics, medical devices, tobacco products and combination products.
VICTORIA LEE, MD
Chief Medical Officer
Dr. Victoria Lee has served as the Company's Senior Vice President & Chief Medical Officer since April of 2023. Previously, Dr. Lee served as the Company's Vice President of Medical Affairs.
Dr. Lee brings extensive experience in clinical affairs and research in the medical technology industry, including in pre-market and post-market clinical trials, collaboration with clinical research organizations and key opinion leaders and general oversight of clinical research operations.